TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA revenue by segment, product and geography
In its fiscal year ending 2025-12-31, TEVA PHARMACEUTICAL INDUSTRIES LTD reported revenue across 4 business segments; the largest, United States Segment, was $9.19B, 53.2% of the filed sum (+14.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- United States Segment$9.19B53.2%+14.3% yoy
- Europe Segment$5.04B29.2%-1.2% yoy
- International Markets$2.16B12.5%-12.2% yoy
- Other Activities$870M5.0%-7.8% yoy
Members sum to the consolidated $17.3B for this period.
- Corporate$5Bshare n/a+15.9% yoy
- United States Segment$3.36Bshare n/a+46.2% yoy
- Europe Segment$1.3Bshare n/a-17.3% yoy
- International Markets$336Mshare n/a-23.6% yoy
- All Other Segments-$90Mshare n/a-600.0% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Product$14.6B84.6%+4.0% yoy
- Distribution Service$1.55B9.0%-1.6% yoy
- License$678M3.9%+291.9% yoy
- Product And Service Other$423M2.5%-43.2% yoy
Members sum to the consolidated $17.3B for this period.
- United States$9.19B64.6%+14.3% yoy
- Europe$5.04B35.4%-1.2% yoy
Members sum to $14.2B against $17.3B consolidated (residual $3.03B) - eliminations or corporate lines the filer did not tag on this axis.
- United States Segment$1.7B41.1%-4.7% yoy
- Europe Segment$1.26B30.5%-2.7% yoy
- Other Activities$627M15.1%+5.0% yoy
- International Markets$550M13.3%+11.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.